Ahlcon Parenterals (India) Peer Comparison
BSE: 524448
₹515.00
As on 21-Jan-2015IST
Market cap
₹371 Cr
Revenue (TTM)
₹176 Cr
P/E Ratio
--
P/B Ratio
4.3
Div. Yield
0 %
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
371 | 31,863 | 30,485 | 28,611 | 27,284 |
Revenue (₹ Cr) |
176 | 3,564 | 1,936 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
-19.79 | 414.00 | 288.22 | -371.81 | 387.35 |
Net Margin (%) |
-10.98 | 11.23 | 14.79 | -3.93 | 26.01 |
RoE (%) |
-- | 8.38 | 29.77 | -3.85 | 25.18 |
Price to Earnings |
-- | 77.90 | 105.77 | -- | 70.64 |
Price-To-Book |
4.31 | 6.33 | 22.71 | 3.57 | 15.78 |
Income Statement (₹ Cr)
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
175.67 | 3,230.00 | 313.57 | 6,559.10 | 520.14 |
|
Total Income
|
180.27 | 3,250.00 | 330.42 | 6,834.90 | 522.90 |
|
Total Expenditure
|
148.96 | 2,932.00 | 352.80 | 5,609.44 | 414.96 |
|
EBITDA
|
26.70 | 298.00 | -39.23 | 949.66 | 105.18 |
|
Depreciation
|
25.47 | 247.00 | 34.01 | 586.18 | 10.08 |
|
EBIT
|
1.23 | 51.00 | -73.24 | 363.48 | 95.10 |
|
Interest
|
25.63 | 299.00 | 9.72 | 198.25 | 6.41 |
|
Other Income
|
4.61 | 20.00 | 16.85 | 275.80 | 2.76 |
|
Exceptional Items
|
-- | -183.00 | -- | -15.08 | -- |
|
Profit before Tax
|
-19.79 | -411.00 | -66.11 | 484.98 | 91.45 |
|
Provision for Tax
|
-- | -132.00 | 1.01 | 109.02 | 19.50 |
|
Profit after Tax
|
-19.79 | -279.00 | -67.12 | 375.96 | 71.95 |
Liabilities (₹ Cr)
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-115.93 | 3,849.00 | 305.40 | 6,696.60 | 522.27 |
|
Minority Interest
|
-- | 353.00 | -- | -- | -- |
|
Non-Current Liabilities
|
259.01 | 261.00 | 70.61 | 2,902.58 | 7.29 |
|
Current Liabilities
|
131.92 | 3,207.00 | 183.51 | 3,118.01 | 129.32 |
|
Total Liabilities
|
275.00 | 8,215.00 | 559.52 | 12,822.45 | 658.88 |
Assets (₹ Cr)
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
205.21 | 5,081.00 | 231.12 | 8,565.30 | 229.31 |
|
Current Assets
|
69.79 | 2,445.00 | 328.40 | 4,151.89 | 429.57 |
|
Total Assets
|
275.00 | 8,215.00 | 559.52 | 12,822.45 | 658.88 |
|
Total Debt*
|
339.30 | 1,862.00 | 169.56 | 4,023.28 | 0.84 |
|
Net Current Assets
|
-62.13 | -762.00 | 144.89 | 1,033.88 | 300.25 |
|
Contingent Liabilities
|
7.74 | 840.00 | 2.01 | 44.94 | 2.70 |
Cashflow (₹ Cr)
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
11.47 | 413.00 | -62.63 | 766.42 | -11.93 |
|
Cash Flow from Investing Activities
|
-3.68 | -201.00 | -54.92 | -1,812.10 | -120.72 |
|
Cash from Financing Activities
|
7.07 | -71.00 | 63.05 | 794.19 | 140.26 |
|
Net Cash Inflow / Outflow
|
14.86 | 141.00 | -54.50 | -251.49 | 7.61 |
Ratios
Profitability Ratios
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
2.65 | -1.96 | -11.97 | 7.10 | 23.85 |
|
ROE (%)
|
0.00 | -7.77 | -20.49 | 6.11 | 21.07 |
|
ROA (%)
|
-7.33 | -3.71 | -12.23 | 3.20 | 13.42 |
|
EBIT Margin (%)
|
17.82 | 9.85 | -7.14 | 18.68 | 20.75 |
|
Net Margin (%)
|
-10.98 | -8.58 | -20.31 | 5.50 | 13.76 |
|
Cash Profit Margin (%)
|
3.24 | -0.62 | -10.56 | 13.17 | 15.77 |
Growth Ratios
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
32.77 | 19.28 | -0.37 | 3.87 | 52.71 |
|
EBIT Growth (%)
|
436.96 | 360.87 | -121.99 | -23.03 | 32.39 |
|
Net Profit Growth (%)
|
57.93 | 6.06 | -318.70 | -54.98 | 33.24 |
|
EPS Growth (%)
|
57.93 | -129.48 | -318.70 | -62.24 | 245.55 |
|
Book Value Growth (%)
|
-20.58 | 14.43 | -19.00 | 19.48 | 224.94 |
Valuation Ratios
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 0.00 | 0.00 | 0.00 | 50.63 |
|
Price / Book Value
|
0.00 | 0.99 | 0.00 | 0.00 | 6.97 |
|
Dividend Yield (%)
|
-- | 0.00 | -- | -- | 0.30 |
|
EV/EBITDA
|
10.58 | 16.52 | -5.45 | 3.98 | 32.83 |
|
Market Cap (₹ Cr)
|
0.00 | 3,798.72 | 0.00 | 0.00 | 3,642.45 |
Solvency Ratios
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-2.93 | 0.49 | 0.58 | 0.60 | 0.00 |
|
Short term debt to equity ratio
|
-0.74 | 0.27 | 0.30 | 0.10 | -- |
|
Current Ratio
|
0.53 | 0.76 | 1.79 | 1.33 | 3.32 |
|
Quick Ratio
|
0.33 | 0.52 | 1.30 | 0.89 | 2.45 |
|
Interest Coverage
|
0.23 | -0.37 | -5.80 | 3.45 | 15.27 |
Operating Efficiency Ratios
| Ahlcon Parenterals (India) | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
13.82 | 28.42 | 44.51 | 27.22 | 31.47 |
|
Asset Turnover
|
0.65 | 0.68 | 0.57 | 0.62 | 0.97 |
|
Receivable days
|
40.71 | 65.29 | 160.50 | 83.94 | 99.79 |
|
Inventory Days
|
47.02 | 55.76 | 88.37 | 65.47 | 60.54 |
|
Payable days
|
58.67 | 232.91 | 252.95 | 144.76 | 135.92 |
|
Cash Conversion Cycle
|
29.05 | -111.86 | -4.08 | 4.65 | 24.41 |